Lexicon Pharmaceuticals (LXRX) Competitors $1.10 -0.02 (-1.79%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.45%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX vs. CLDX, INVA, NVAX, DVAX, OPK, ZBIO, GERN, RIGL, MYGN, and VSTMShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), Zenas BioPharma (ZBIO), Geron (GERN), Rigel Pharmaceuticals (RIGL), Myriad Genetics (MYGN), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. Its Competitors Celldex Therapeutics Innoviva Novavax Dynavax Technologies OPKO Health Zenas BioPharma Geron Rigel Pharmaceuticals Myriad Genetics Verastem Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Which has stronger earnings and valuation, CLDX or LXRX? Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M232.53-$157.86M-$3.01-8.17Lexicon Pharmaceuticals$31.08M12.86-$200.40M-$0.33-3.33 Does the media favor CLDX or LXRX? In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 5 mentions for Celldex Therapeutics. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Celldex Therapeutics' score of 1.16 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in CLDX or LXRX? 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, CLDX or LXRX? Celldex Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Do analysts recommend CLDX or LXRX? Celldex Therapeutics presently has a consensus target price of $46.67, indicating a potential upside of 89.86%. Lexicon Pharmaceuticals has a consensus target price of $3.23, indicating a potential upside of 193.18%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CLDX or LXRX more profitable? Lexicon Pharmaceuticals has a net margin of -206.43% compared to Celldex Therapeutics' net margin of -3,446.88%. Celldex Therapeutics' return on equity of -27.61% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-3,446.88% -27.61% -26.20% Lexicon Pharmaceuticals -206.43%-83.63%-42.22% SummaryLexicon Pharmaceuticals beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks. Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$407.01M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-3.3321.1676.1526.51Price / Sales12.86446.35523.22123.62Price / CashN/A45.4037.1760.46Price / Book2.759.6213.686.29Net Income-$200.40M-$53.28M$3.29B$270.60M7 Day Performance1.85%1.01%0.84%1.95%1 Month Performance-11.29%4.58%4.63%6.33%1 Year Performance-32.10%8.35%81.08%25.61% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals2.5523 of 5 stars$1.10-1.8%$3.23+193.2%-32.5%$407.01M$31.08M-3.33140CLDXCelldex Therapeutics2.234 of 5 stars$23.40+2.3%$46.67+99.4%-42.7%$1.55B$7.02M-7.77150INVAInnoviva4.8345 of 5 stars$20.46-0.1%$42.75+108.9%-3.5%$1.29B$358.71M66.00100Positive NewsShort Interest ↓NVAXNovavax4.3229 of 5 stars$7.73-2.2%$14.29+84.8%-35.2%$1.26B$682.16M3.391,990DVAXDynavax Technologies4.4113 of 5 stars$9.70-3.6%$24.33+150.9%-13.0%$1.14B$277.25M-21.09350Positive NewsOPKOPKO Health4.372 of 5 stars$1.42+5.2%$2.75+93.7%-15.2%$1.13B$713.10M-5.682,997ZBIOZenas BioPharma1.159 of 5 stars$21.52+4.9%$36.67+70.4%N/A$906.21M$5M-6.06N/AHigh Trading VolumeGERNGeron3.1372 of 5 stars$1.37-2.1%$4.19+205.7%-71.4%$874.09M$76.99M-10.5470Positive NewsRIGLRigel Pharmaceuticals2.4814 of 5 stars$40.87-1.1%$38.20-6.5%+154.4%$733.21M$179.28M7.55160Positive NewsHigh Trading VolumeMYGNMyriad Genetics3.5777 of 5 stars$6.91+4.5%$12.45+80.2%-73.1%$642.91M$837.60M-1.612,700VSTMVerastem2.8791 of 5 stars$10.23-5.0%$13.29+29.9%+234.4%$629.55M$10K-3.1250Positive News Related Companies and Tools Related Companies CLDX Alternatives INVA Alternatives NVAX Alternatives DVAX Alternatives OPK Alternatives ZBIO Alternatives GERN Alternatives RIGL Alternatives MYGN Alternatives VSTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXRX) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts